Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., based in Cambridge, Massachusetts, is a pioneering biopharmaceutical company that has led the successful translation of RNA interference (RNAi) into an entirely new class of innovative medicines. Founded in 2002, Alnylam was built upon the Nobel Prize-winning discovery of RNAi, a natural biological process used to silence specific genes.

For over a decade, the company tirelessly worked to solve the immense scientific challenge of delivering fragile siRNA (small interfering RNA) molecules to target organs in the human body. Their perseverance paid off with the invention of their proprietary lipid nanoparticle (LNP) and Enhanced Stabilization Chemistry (ESC)-GalNAc conjugate delivery platforms, which effectively route the therapies directly to the liver.

This scientific breakthrough culminated in the approval of Onpattro, the world’s first RNAi therapeutic, used to treat a rare, life-threatening genetic disease. Since then, Alnylam has rapidly commercialized several other groundbreaking therapies, including Givlaari, Oxlumo, and Amvuttra, solidifying its position as the undisputed global leader in RNAi.

The company is primarily focused on severe rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) disorders. Alnylam operates a massive, state-of-the-art commercial manufacturing facility in Norton, Massachusetts, designed specifically for oligonucleotide production. Known for its deeply entrenched scientific culture and strategic partnerships with companies like Novartis and Regeneron, Alnylam continues to aggressively expand its pipeline, promising to silence disease-causing genes and address massive unmet medical needs globally.